All Outputs (2)

Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin-; the role of phosphodiesterase 3A. (2019)
Journal Article
Berger, M., Raslan, Z., Aburima, A., Magwenzi, S., Wraith, K. S., Spurgeon, B. E., Hindle, M. S., Law, R., Febbraio, M., & Naseem, K. M. (2020). Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin-; the role of phosphodiesterase 3A. Haematologica, 105(3), 808-819. https://doi.org/10.3324/haematol.2018.213348

©2020 Ferrata Storti Foundation Prostacyclin (PGI2) controls platelet activation and thrombosis through a cyclic adenosine monophosphate (cAMP) signaling cascade. However, in patients with cardiovascular diseases this protective mechanism fails for r... Read More about Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin-; the role of phosphodiesterase 3A..

cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway (2013)
Journal Article
Aburima, A., Wraith, K. S., Raslan, Z., Law, R., Magwenzi, S., & Naseem, K. M. (2013). cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway. Blood, 122(20), 3533-3545. https://doi.org/10.1182/blood-2013-03-487850

Cyclic adenosine monophosphate (cAMP)-dependent signaling modulates platelet shape change through unknown mechanisms. We examined the effects of cAMP signaling on platelet contractile machinery. Prostaglandin E1 (PGE1)-mediated inhibition of thrombin... Read More about cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway.